David J Leggat
Overview
Explore the profile of David J Leggat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
403
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mwesigwa B, Sawe F, Oyieko J, Mwakisisile J, Viegas E, Akintunde G, et al.
Clin Infect Dis
. 2024 Apr;
79(4):888-900.
PMID: 38657084
Background: Shorter prophylactic vaccine schedules may offer more rapid protection against Ebola in resource-limited settings. Methods: This randomized, observer-blind, placebo-controlled, phase 2 trial conducted in 5 sub-Saharan African countries included...
2.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
NPJ Vaccines
. 2024 Mar;
9(1):58.
PMID: 38467663
Vaccine priming immunogens that activate germline precursors for broadly neutralizing antibodies (bnAbs) have promise for development of precision vaccines against major human pathogens. In a clinical trial of the eOD-GT8...
3.
Scholte L, Leggat D, Cohen K, Hoeweler L, Erwin G, Rahaman F, et al.
STAR Protoc
. 2023 Sep;
4(4):102576.
PMID: 37733596
The lymph node (LN) is a critical biological site for immune maturation after vaccination as it includes several cell populations critical for priming the antibody response. Here, we present a...
4.
Cohen K, De Rosa S, Fulp W, deCamp A, Fiore-Gartland A, Mahoney C, et al.
Sci Transl Med
. 2023 May;
15(697):eadf3309.
PMID: 37224227
The engineered outer domain germline targeting version 8 (eOD-GT8) 60-mer nanoparticle was designed to prime VRC01-class HIV-specific B cells that would need to be matured, through additional heterologous immunizations, into...
5.
deCamp A, Corcoran M, Fulp W, Willis J, Cottrell C, Bader D, et al.
medRxiv
. 2023 Mar;
PMID: 36993183
One-sentence Summary: Human genetic variation can modulate the strength of vaccine-induced broadly neutralizing antibody precursor B cell responses.
6.
Leggat D, Cohen K, Willis J, Fulp W, deCamp A, Kalyuzhniy O, et al.
Science
. 2022 Dec;
378(6623):eadd6502.
PMID: 36454825
Broadly neutralizing antibodies (bnAbs) can protect against HIV infection but have not been induced by human vaccination. A key barrier to bnAb induction is vaccine priming of rare bnAb-precursor B...
7.
Townsley S, Leggat D, Prabhakaran M, McDermott A, Krebs S
STAR Protoc
. 2021 Sep;
2(3):100771.
PMID: 34471908
Protocols for efficient capture of antigen-specific B cells (ASBCs) are useful for understanding pathogen-specific B-cell responses during natural infection or vaccination. Fluorescently labeled tetramerized probes are classically used to capture...
8.
Townsley S, Donofrio G, Jian N, Leggat D, Dussupt V, Mendez-Rivera L, et al.
Cell Host Microbe
. 2021 Mar;
29(4):564-578.e9.
PMID: 33662277
Determining which immunological mechanisms contribute to the development of broad neutralizing antibodies (bNAbs) during HIV-1 infection is a major goal to inform vaccine design. Using samples from a longitudinal HIV-1...
9.
Eslamizar L, Petrovas C, Leggat D, Furr K, Lifton M, Levine G, et al.
NPJ Vaccines
. 2021 Jan;
6(1):15.
PMID: 33495459
The RV144 HIV-1 vaccine trial has been the only clinical trial to date that has shown any degree of efficacy and associated with the presence of vaccine-elicited HIV-1 envelope-specific binding...
10.
Dussupt V, Sankhala R, Gromowski G, Donofrio G, De La Barrera R, Larocca R, et al.
Nat Med
. 2020 Feb;
26(2):228-235.
PMID: 32015557
Zika virus (ZIKV) has caused significant disease, with widespread cases of neurological pathology and congenital neurologic defects. Rapid vaccine development has led to a number of candidates capable of eliciting...